TG THERAPEUTICS INC. - COMMON STOCK

35.07

22-November-24 16:44:58

15 minutes delayed

Stocks

+0.52

+1.51%

Today's range

33.71 - 35.32

ISIN

N/A

Source

NASDAQ

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

27 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

03 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

01 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

12 Oct 2023 11:00:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

11 Oct 2023 10:30:26 By Nasdaq GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

02 Oct 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

22 Sep 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

01 Aug 2023 07:15:00 By Nasdaq GlobeNewswire
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

01 Aug 2023 07:00:01 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update

31 Jul 2023 08:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

05 Jun 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

02 Jun 2023 09:15:20 By Nasdaq GlobeNewswire
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

01 Jun 2023 09:15:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

31 May 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference

04 May 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

01 May 2023 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

28 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.